Clinical Trial Update: ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS) [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of intrathecally administered ION440 in individuals with M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mecp2 Duplication Syndrome

Drugs mentioned

• ION440

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Phase 1, Phase 2 | Status: RECRUITING